Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 103 of 5804
-
Could a shot help people with multiple food allergies eat peanuts safely?
Disease control CompletedThis study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergi…
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 16:10 UTC
-
Personalized mRNA vaccine shows promise in fighting melanoma return
Disease control OngoingThe purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immunotherapy plus chemo shows promise in advanced uterine cancer trial
Disease control OngoingThis is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplat…
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:51 UTC
-
Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill shows promise for regrowing hair in severe alopecia
Disease control CompletedThe reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a gut hormone boost islet transplants and free type 1 diabetes patients from insulin shots?
Disease control Recruiting nowThis clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control. This study involves two investigational (experimental) pr…
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising combo therapy aims to beat back childhood blood cancers
Disease control OngoingThis phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Promising combo may delay drug resistance in lung cancer patients
Disease control OngoingThe reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cel…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise against deadly thyroid cancer
Disease control OngoingThis study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Training the immune system to hunt down leftover liver cancer cells
Prevention OngoingHepatocellular carcinoma (HCC) is the most common primary liver tumor. Surgical resection remains the first choice for early-stage HCC because the result is superior to other treatments and not limited to liver donation. However, liver resection is criticized because the tumor re…
Phase: PHASE2 • Sponsor: Chang Gung Memorial Hospital • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
New 9-Valent HPV vaccine aims to shield chinese women from more Cancer-Causing strains
Prevention OngoingThis study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age. The primary hypotheses are: 9vHPV vaccine reduces the incidence of HPV 31-, 33-, 45-, 52-, and 58-related 12-month persi…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug combo in final testing
Disease control OngoingPhase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New triple therapy aims to stall advanced kidney cancer
Disease control OngoingThis is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanc…
Phase: PHASE3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
Engineered immune cells take aim at stubborn childhood leukemia
Disease control OngoingThis is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Diabetes drug semaglutide may shield your heart
Disease control CompletedThe researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Bladder cancer drug combo shows promise in major trial
Disease control CompletedA global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo shows promise in High-Risk prostate cancer trial
Disease control OngoingThe purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer result…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Cholesterol-Lowering drug aims to stop first heart attacks
Disease control CompletedThis study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
App alerts heroes: volunteers with defibrillators rush to cardiac arrests
Disease control CompletedThe study will assess 30-day survival for cases where volunteer citizen responders ('heart runners') were activated through a smartphone app to retrieve an AED in case of suspected out-of-hospital cardiac arrest (OHCA) versus standard emergency medical services care. The study wi…
Phase: NA • Sponsor: Emergency Medical Services, Capital Region, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill could offer hope for advanced breast cancer patients
Disease control CompletedThis Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhi…
Phase: PHASE3 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC